Guerbet
Guerbet is a global leader in medical imaging, specializing in contrast media, pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging. With over 90 years of experience and more than 2,600 employees worldwide, Guerbet is committed to innovation, research, and building lasting relationships to improve patient diagnosis and treatment.
Industries
Nr. of Employees
large (251-1000)
Patents
Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
US-12064487-B2
View Details
Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
US-12064487-B2
View DetailsProducts
Oil‑based iodized contrast agent for HSG and interventional oncology
An oil‑soluble iodized poppyseed oil formulation used for hysterosalpingography and as a procedure visualizer, drug vehicle and embolic in trans‑arterial chemoembolization procedures.
Lipiodol‑resistant mixing & injection device set for cTACE
A sterile single‑use kit containing Lipiodol‑resistant syringes, multi‑port stopcock and sampling devices validated for up to 24 hours of exposure to oil‑based contrast agents to facilitate mixing and on‑table refill during cTACE.
Flow‑control microcatheter for embolization
A microcatheter engineered with side‑slit/flow dynamics features to create a fluid barrier that reduces microsphere reflux and improves targeted delivery during embolization procedures.
Consumables portfolio for injection systems
Two-tier range of consumables (certified essential and higher‑specification excellence ranges) including syringes, tubing, patient lines and kits compatible with diagnostic injection systems.
AI image‑analysis solutions for oncology and neuroimaging
Development and co‑development of AI tools to detect, segment, quantify and monitor lesions in MRI/CT to support diagnosis and follow‑up in oncology and neurological disorders; tools designed for PACS integration and clinical workflow use.
Oil‑based iodized contrast agent for HSG and interventional oncology
An oil‑soluble iodized poppyseed oil formulation used for hysterosalpingography and as a procedure visualizer, drug vehicle and embolic in trans‑arterial chemoembolization procedures.
Lipiodol‑resistant mixing & injection device set for cTACE
A sterile single‑use kit containing Lipiodol‑resistant syringes, multi‑port stopcock and sampling devices validated for up to 24 hours of exposure to oil‑based contrast agents to facilitate mixing and on‑table refill during cTACE.
Flow‑control microcatheter for embolization
A microcatheter engineered with side‑slit/flow dynamics features to create a fluid barrier that reduces microsphere reflux and improves targeted delivery during embolization procedures.
Consumables portfolio for injection systems
Two-tier range of consumables (certified essential and higher‑specification excellence ranges) including syringes, tubing, patient lines and kits compatible with diagnostic injection systems.
AI image‑analysis solutions for oncology and neuroimaging
Development and co‑development of AI tools to detect, segment, quantify and monitor lesions in MRI/CT to support diagnosis and follow‑up in oncology and neurological disorders; tools designed for PACS integration and clinical workflow use.
Services
Commercial distribution and local market deployment of cloud/SaaS AI imaging solutions for neuroimaging and oncology, including commercial and technical support.
Regulatory submission support, market registration and post‑approval medical affairs to secure indications and facilitate clinical adoption for imaging pharmaceuticals and devices.
Commercial distribution and local market deployment of cloud/SaaS AI imaging solutions for neuroimaging and oncology, including commercial and technical support.
Regulatory submission support, market registration and post‑approval medical affairs to secure indications and facilitate clinical adoption for imaging pharmaceuticals and devices.
Expertise Areas
- Contrast agent development and formulation
- Interventional oncology therapies and locoregional drug delivery
- Medical device development for interventional radiology
- Clinical trial management and evidence generation
Key Technologies
- Oil‑based iodized contrast agents for imaging and drug delivery
- Iodinated and gadolinium‑based contrast media
- Microcatheter reflux‑control (fluid barrier) technology
- Lipiodol‑resistant mixing and injection device systems
News & Updates
Guerbet Australia announced TGA approval of Elucirem™ (Gadopiclenol) for contrast-enhanced MRI.
Guerbet announced changes in its Board of Directors.
Guerbet released its Q1 2025 revenue report.
Guerbet announced its H1 2025 revenue figures.
Guerbet offers a full range of medical solutions in diagnostic and interventional imaging.
Guerbet was ranked the best company in the healthcare category by Gaïa-Index in 2020.
Guerbet Australia announced TGA approval of Elucirem™ (Gadopiclenol) for contrast-enhanced MRI.
Guerbet announced changes in its Board of Directors.
Guerbet released its Q1 2025 revenue report.
Guerbet announced its H1 2025 revenue figures.
Guerbet offers a full range of medical solutions in diagnostic and interventional imaging.
Guerbet was ranked the best company in the healthcare category by Gaïa-Index in 2020.